Clinical trials: Normal Tension Glaucoma (NTG)
Normal Tension Glaucoma, Primary Open-angle Glaucoma
Study in Prostaglandin Associated Peri-orbitopathy Switching From Prostaglandin Monotherapy to Omidenepag Isopropyl
This study is for patients have been using prostaglandin analogue eye drops with a preservative for 3 months or more and have been diagnosed with prostaglandin-associated peri-orbital disease.
- Conditions
- Normal Tension Glaucoma, Primary Open-angle Glaucoma, Glaucoma, Suspect, Ocular Hypertension
- Trial name
- NOPAPS (NCT05279716)
- Testing
- Eybelis ophthalmic solution 0.002%
- Where
- 8 sites in South Korea
- Volunteers
- 150 people
- Sponsor
- Santen Pharmaceutical Asia Pte. Ltd.
Glaucoma, GLAUCOMA 1, OPEN ANGLE, D (Disorder)
24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring
The goal of this clinical trial is to learn if a new contact lens device can record patterns in eye pressure for 24 hours in adults with glaucoma and in healthy participants.
- Conditions
- Glaucoma, GLAUCOMA 1, OPEN ANGLE, D (Disorder), Ocular Hypertension, Ocular Hypertension (OH)
- Trial name
- NCT06689696
- Testing
- miLens system
- Where
- 3 sites in United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Smartlens, Inc.
Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG)
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG
- Conditions
- Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG), Normal Tension Glaucoma (NTG)
- Trial name
- (PENGUIN) (NCT07354477)
- Testing
- QLS-111 Ophthalmic Solution (0.015%), QLS-111 Ophthalmic Solution (0.075%)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Qlaris Bio, Inc.
Glaucoma, Open-Angle, Normal Tension Glaucoma
Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)
The objective of this study is to evaluate the long-term efficacy and safety of COMBIGAN® (brimonidine tartrate/timolol malate) in patients only using COMBIGAN® (brimonidine tartrate/timolol malate) and also in patients who…
- Trial name
- NCT02863705
- Testing
- brimonidine tartrate/timolol malate Ophthalmic Solution, bimatoprost ophthalmic solution 0.01%
- Where
- 9 sites in South Korea
- Volunteers
- 118 people
- Sponsor
- Allergan
Normal Tension Glaucoma (NTG)
A Study to Evaluate Safety and Tolerability of QLS-101 in NTG
A randomized active-controlled multi-site double-masked 28 day study to evaluate the safety and tolerability of QLS-101 versus timolol maleate Preservative Free (PF) 0.5% ophthalmic solution in subjects with normal tension…
- Trial name
- NCT04857827
- Testing
- QLS-101, Timolol maleate PF 0.5% ophthalmic solution
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Qlaris Bio, Inc.
Normal Tension Glaucoma (NTG), Low-Tension Glaucoma, Bilateral
Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)
Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in normal tension glaucoma patients.
- Conditions
- Normal Tension Glaucoma (NTG), Low-Tension Glaucoma, Bilateral, Low-Tension Glaucoma, Unspecified Eye, Glaucoma
- Trial name
- Nightingale (NCT06030193)
- Testing
- QLS-111 ophthalmic solution (0.015%), Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol)
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Qlaris Bio, Inc.
Low Tension Glaucoma
Observational Study of the Long-term Effect of Latanoprost in Normal Tension Glaucoma
The purpose of this study is to assess the long-term efficacy and safety of latanoprost monotherapy in patients with normal tension glaucoma (NTG) using a prospective, observational design.
- Trial name
- NTG-X-PERT (NCT01209624)
- Volunteers
- 902 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.